<DOC>
	<DOCNO>NCT00682227</DOCNO>
	<brief_summary>The purpose study evaluate safety immunological monitoring peptide vaccination therapy use novel cancer testis antigens locally advanced , recurrent , metastatic esophageal squamous cell carcinoma</brief_summary>
	<brief_title>Peptide Vaccination Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>We recently identify three HLA-A2402-restricted epitope peptide ( TTK protein kinase ( TTK ) , lymphocyte antigen 6 complex locus K ( LY6K ) , insulin-like growth factor ( IGF ) -II mRNA binding protein 3 ( IMP-3 ) ) derive novel Cancer-Testis antigen ( CTA ) development immunotherapy esophageal squamous cell carcinoma ( ESCC ) , report pre-existence specific T cell response epitope peptide frequently see ESCC patient . Then , perform Phase I vaccination trial use multi-epitopes involve TTK , LY6K , IMP-3 peptides locally advanced , recurrent metastatic esophageal squamous cell carcinoma fail standard therapy . Each three HLA-A2402-restricted epitope peptide mixed IFA inject every week five round . Primary endpoint evaluate safety feasibility therapy . Secondary endpoint investigate immunological monitoring clinical effect .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1 . Locally advanced , recurrent metastatic esophageal squamous cell carcinoma fail standard therapy PATIENTS CHARACTERISTICS 1 . ECOG performance status 02 2 . Age≧20 year , 80≦years 3 . WBC≥ 2,000/mm³ Platelet count ≥ 75,000/mm³ Total bilirubin ≤ 2.0 x institutional normal upper limit AST , ALT , ALP ≤ 2.5 x institutional normal upper limit Creatinine ≤ 1.5 x institutional normal upper limit 4 . Patients must HLAA2402 5 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Serious bleed disorder 4 . Serious infection require antibiotic 5 . Concomitant treatment steroid immunosuppressing agent 6 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Epitope peptide , CTL , Esophageal cancer , Vaccination</keyword>
</DOC>